---
title: "LB Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286153418.md"
datetime: "2026-05-12T20:31:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286153418.md)
  - [en](https://longbridge.com/en/news/286153418.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286153418.md)
---

# LB Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.67, beating the estimate of USD -0.745.

EBIT: As of FY2026 Q1, the actual value is USD -24.95 M.

### Operational Metrics

-   **Research & Development Expenses**: Research and development expenses for LB Pharmaceuticals Inc were $14.6 million for the three months ended March 31, 2026, an increase of $11.2 million compared to $3.4 million for the three months ended March 31, 2025.
-   **General & Administrative Expenses**: General and administrative expenses were $7.5 million for the three months ended March 31, 2026, an increase of $4.5 million from $3.0 million for the three months ended March 31, 2025.
-   **Net Loss**: LB Pharmaceuticals Inc reported a net loss of - $19.1 million for the three months ended March 31, 2026, compared to a net loss of - $5.3 million for the same period in 2025.
-   **Total Operating Loss**: The total operating loss was - $22,104 thousand for Q1 2026, compared to - $6,429 thousand for Q1 2025.
-   **Loss Before Income Tax**: Loss before income tax was - $19,054 thousand for Q1 2026, compared to - $5,306 thousand for Q1 2025.
-   **Income Tax Provision**: The income tax provision was $0 for both Q1 2026 and Q1 2025.

### Other Financial Metrics

-   **Interest Income**: Interest income was $2,850 thousand for Q1 2026, up from $236 thousand for Q1 2025.
-   **Realized Gain on Sale of Marketable Securities, Net**: This metric was $0 for Q1 2026, compared to $119 thousand for Q1 2025.
-   **Gain on Change in Fair Value of Derivative Instruments**: This gain was $200 thousand for Q1 2026, compared to $768 thousand for Q1 2025.
-   **Total Non-Operating Income**: Total non-operating income amounted to $3,050 thousand for Q1 2026, compared to $1,123 thousand for Q1 2025.

### Cash Position

-   **Cash, Cash Equivalents, and Marketable Securities**: As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $365.6 million, an increase from $295.2 million as of December 31, 2025.

### Balance Sheet Highlights (in thousands)

-   **Total Assets**: Total assets were $393,482 as of March 31, 2026, compared to $312,934 as of December 31, 2025.
-   **Total Liabilities**: Total liabilities were $14,789 as of March 31, 2026, compared to $11,624 as of December 31, 2025.
-   **Total Stockholders’ Equity**: Total stockholders’ equity stood at $378,693 as of March 31, 2026, compared to $301,310 as of December 31, 2025.

### Outlook / Guidance

LB Pharmaceuticals Inc expects its cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026, to fund operations into the second quarter of 2029. The company anticipates releasing topline data from the NOVA-2 trial in schizophrenia in the second half of 2027, and from the ILLUMINATE-1 trial in bipolar depression in the first quarter of 2028. Additionally, topline data from the adjunctive MDD trial is expected in the first half of 2029.

### Related Stocks

- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)

## Related News & Research

- [Craig-Hallum Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)](https://longbridge.com/en/news/286273988.md)
- [Faron Pharmaceuticals LTD: Holding(s) In Company](https://longbridge.com/en/news/286725255.md)
- [PMV Pharmaceuticals (NASDAQ:PMVP) Will Have To Spend Its Cash Wisely](https://longbridge.com/en/news/286912396.md)
- [Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA | HNSA Stock News](https://longbridge.com/en/news/286864132.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)